The efficiency of Neuromidin in the comprehensive treatment of diabetic distal symmetric polyneuropath
Keywords:type 2 diabetes mellitus, distal symmetric polyneuropathy, electroneuromyography, Neuromidin
Background. The purpose of the study is to establish the efficiency and safety of the use of ipidacrine (Neuromidin) in patients with type 2 diabetes mellitus complicated by distal symmetric polyneuropathy. Materials and methods. One hundred ten patients with distal symmetric polyneuropathy were examined. Selected patients were divided into 2 groups: group I (n = 24) — persons receiving basic treatment; group II (n = 50) — patients who received Neuromidin, in the form of intramuscular injections of 5 mg 2 times a day for 10 days, then orally 20 mg 3 times a day for 20 days. All patients underwent neurological examination using Neuropathy Symptom Score, Neuropathy Disability Score, electroneuromyographic (ENMG) testing of the peripheral nerves of the lower extremities. In order to establish the peculiarities of cognitive functions, Mini-Mental State Examination was used. Also, the rates of anxiety and depression in the dynamics of treatment were assessed. Results. In the group of people who received Neuromidin on the background of basic treatment, there was a significant improvement in the subjective and objective symptoms. The manifestations of axonopathy and myelinopathy according to the results of ENMG testing of peripheral nerves were believed to decrease in the group of patients taking Neuromidin against the background of basic treatment. Also, a statistically significant improvement of cognitive functions, reduction of anxiety and depression manifestations was established with the administration of Neuromidin. Conclusions. The application of Neuromidin on the background of basic therapy in patients with distal symmetric polyneuropathy improves the processes of regeneration and reinnervation of the peripheral nerves of the lower extremities and improves motor fibers conduction according to the ENMG parameters, has a positive effect on the clinical course of the disease, as well as improves cognitive function, reduces manifestations of anxiety and depression.
Lomova-Williams L, Mallipedhi A, MacIver C, et al. Research letter in relation to paper by Bongaerts et al., a clinical screening score for diabetic polyneuropathy: KORA F4 and AusDiab studies. J Diabetes Complications. 2015 Mar;29(2):318-9. doi: 10.1016/j.jdiacomp.2014.11.016.
Oros MM, Smolanka VI, Yathynyn RYu, Savytska NO. Paresis in neuropathy and radiculopathy: treatment tactics. International neurological journal. 2017;(94):53-55. doi: 10.22141/2224-0718.104.22.1687.120701. (in Ukrainian).
Pashkovska NV, Pashkovsky VM. Dynamics of indicators of cognitive functions and emotional and personal reactions in patients with diabetic encephalopathy under the influence of treatment with neuromidin. Ukrainian Neurological Journal. 2012;(24):67-72. (in Ukrainian).
How to Cite
Copyright (c) 2019 N.V. Pashkovska, V.M. Pashkovsky, I.А. Zoriy
This work is licensed under a Creative Commons Attribution 4.0 International License.